Regeneron Pharmaceuticals (NASDAQ:REGN) Lifted to Strong-Buy at StockNews.com

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was upgraded by research analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a research report issued on Friday.

Several other brokerages have also recently commented on REGN. Truist Financial reiterated a "buy" rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Bank of America lifted their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an "underperform" rating in a research report on Friday. Royal Bank of Canada restated an "outperform" rating and issued a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday. Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an "overweight" rating in a report on Wednesday, March 13th. Finally, Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an "outperform" rating and a $1,125.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $970.57.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded down $15.62 during mid-day trading on Friday, reaching $904.70. The stock had a trading volume of 665,264 shares, compared to its average volume of 491,976. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The business has a 50 day simple moving average of $957.56 and a 200 day simple moving average of $888.71. Regeneron Pharmaceuticals has a twelve month low of $684.80 and a twelve month high of $998.33. The firm has a market capitalization of $99.30 billion, a price-to-earnings ratio of 26.03, a PEG ratio of 2.73 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts' consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the previous year, the business earned $10.96 earnings per share. The company's revenue for the quarter was up .6% compared to the same quarter last year. On average, analysts expect that Regeneron Pharmaceuticals will post 38.18 earnings per share for the current fiscal year.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares in the company, valued at approximately $17,540,472.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares of the company's stock, valued at approximately $46,203,239.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Arthur F. Ryan sold 100 shares of the business's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the sale, the director now directly owns 18,382 shares of the company's stock, valued at approximately $17,540,472.04. The disclosure for this sale can be found here. Insiders sold a total of 13,729 shares of company stock valued at $13,124,641 over the last quarter. Company insiders own 8.83% of the company's stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of REGN. Sunbelt Securities Inc. acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $26,000. O Dell Group LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $27,000. Fortitude Family Office LLC purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $31,000. Finally, MCF Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 12 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.